TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARa, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequendy observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological because fenofibrate activates the gene expression of the aminotransferases. Recendy, fenofibrate has been used not only for hypercholesterolemia but also for primary biliary cirrhosis (PBC). However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug. TO THE EDITOR Fenofibrate is a member of such fibrate class agents as bezafibrate and it work as a ligand of PPARa, and also shows a potent triglyceride-lowering effect. The elevation of aminotransferase levels has been frequendy observed after the administration of fenofibrate and this phenomenon is considered to be non-pathological for fenofibrate activates the gene expression of the aminotransferases. However, the occurrence of liver injury induced by fenofibrate has not yet been reported written in the English literature. We herein report a rare case of liver injury due to the oral use of this drug.